Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials

Nawaf, Cayce; Shiang, Alexander; Chauhan, Pradeep S.; Chaudhuri, Aadel A.; Agarwal, Gautum; Smith, Zachary L.

doi:10.1016/j.tranon.2023.101763

Cited by 4 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, ctDNA has become a powerful biomarker in oncology because of its utility in monitoring molecular relapse and treatment response or detecting molecular residual disease in multiple cancer types [4,8,15,16], including BC [9,12,[17][18][19][20][21]. Using a tumor-informed approach to evaluate serial cfDNA samples from MIBC patients [13], we were able to demonstrate that a positive ctDNA status four months after RC had prognostic implications.…”

Section: Discussionmentioning

confidence: 95%

Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer

Carrasco,

Ingelmo-Torres,

Trullas

et al. 2023

IJMS

View full text Add to dashboard Cite

Circulating tumor DNA (ctDNA) has recently emerged as a real-time prognostic and predictive biomarker for monitoring cancer patients. Here, we aimed to ascertain whether tumor-agnostic ctDNA testing would be a feasible strategy to monitor disease progression and therapeutic response in muscle-invasive bladder cancer (MIBC) patients after radical cystectomy (RC). Forty-two MIBC patients who underwent RC were prospectively included. Blood samples from these patients were collected at different follow-up time points. Two specific mutations (TERT c.1-124C>T and ATM c.1236-2A>T) were analyzed in the patients’ plasma samples by droplet digital PCR to determine their ctDNA status. During a median follow-up of 21 months, 24% of patients progressed in a median of six months. ctDNA status was identified as a prognostic biomarker of tumor progression before RC and 4 and 12 months later (HR 6.774, HR 3.673, and HR 30.865, respectively; p < 0.05). Lastly, dynamic changes in ctDNA status between baseline and four months later were significantly associated with patient outcomes (p = 0.045). In conclusion, longitudinal ctDNA analysis using a tumor-agnostic approach is a potential tool for monitoring MIBC patients after RC. The implementation of this testing in a clinical setting could improve disease management and patients’ outcomes.

show abstract

Section: Discussionmentioning

confidence: 95%

Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer

Carrasco,

Ingelmo-Torres,

Trullas

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Thus, a non-invasive biomarker to detect disease recurrence is urgently needed to reduce morbidity and mortality [ 132 ]. Clinically available assays, such as the Signatera MRD test, are ctDNA-based tests used for risk stratification and monitoring of treatment response in bladder cancer [ 117 , 133 ]. In the ABACUS trial, ctDNA was found to be prognostic at baseline, after atezolizumab therapy, and post-radical cystectomy, with a prevalence of 63%, 47%, and 14% at the respective time points [ 122 ].…”

Section: Clinical Significancementioning

confidence: 99%

Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications

Gerke,

Jansen,

Bilen

2024

Cancers

View full text Add to dashboard Cite

CtDNA is emerging as a non-invasive clinical detection method for several cancers, including genitourinary (GU) cancers such as prostate cancer, bladder cancer, and renal cell carcinoma (RCC). CtDNA assays have shown promise in early detection of GU cancers, providing prognostic information, assessing real-time treatment response, and detecting residual disease and relapse. The ease of obtaining a “liquid biopsy” from blood or urine in GU cancers enhances its potential to be used as a biomarker. Interrogating these “liquid biopsies” for ctDNA can then be used to detect common cancer mutations, novel genomic alterations, or epigenetic modifications. CtDNA has undergone investigation in numerous clinical trials, which could address clinical needs in GU cancers, for instance, earlier detection in RCC, therapeutic response prediction in castration-resistant prostate cancer, and monitoring for recurrence in bladder cancers. The utilization of liquid biopsy for ctDNA analysis provides a promising method of advancing precision medicine within the field of GU cancers.

show abstract

Reply to Chao Song’s Letter to the Editor re: Florus C. de Jong, Iris G. Iflé, Angelique C. van der Made, et al. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy. Eur Urol Open Sci 2024;62:131–9

de Jong,

Zuiverloon,

Boormans

2024

European Urology Open Science

View full text Add to dashboard Cite

Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials

Cited by 4 publications

References 44 publications

Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer

Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer

Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications

Reply to Chao Song’s Letter to the Editor re: Florus C. de Jong, Iris G. Iflé, Angelique C. van der Made, et al. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy. Eur Urol Open Sci 2024;62:131–9

Contact Info

Product

Resources

About